Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01874431 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 823
- Enrollment target
NCT01874431 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 823 participants.
The verdict
NCT01874431, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 823 participants
- Enrollment target
Study Summary
To assess a new drug, BAY94-8862 given orally at different doses, to evaluate whether it was safe and can help the well being of patients with type 2 diabetes and diabetic nephropathy. These treatment doses were compared to placebo.
Interventions
- DRUG Placebo
- DRUG Finerenone (BAY94-8862)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 823 participants |
| Start Date | 2013-06-12 |
| Est. Completion | 2014-08-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01874431
The ClinicalTrials.gov registry entry for NCT01874431 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 823 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01874431 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01874431 about?
NCT01874431 is a clinical study titled "Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy". To assess a new drug, BAY94-8862 given orally at different doses, to evaluate whether it was safe and can help the well being of patients with type 2 diabetes and diabetic nephropathy. These treatment doses were compared to placebo.
What is the current status of trial NCT01874431?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 823 participants. The study started on 2013-06-12. Estimated completion is 2014-08-07.
What interventions are being tested in trial NCT01874431?
The interventions under investigation include: Placebo (DRUG), Finerenone (BAY94-8862) (DRUG).
Who is sponsoring clinical trial NCT01874431?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.